Compare HUN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUN | AGIO |
|---|---|---|
| Founded | 1970 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2005 | 2013 |
| Metric | HUN | AGIO |
|---|---|---|
| Price | $10.09 | $24.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $10.23 | ★ $32.13 |
| AVG Volume (30 Days) | ★ 5.5M | 1.7M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,780,000,000.00 | $44,791,000.00 |
| Revenue This Year | N/A | $28.75 |
| Revenue Next Year | $3.40 | $139.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 36.26 |
| 52 Week Low | $7.30 | $22.24 |
| 52 Week High | $18.53 | $46.00 |
| Indicator | HUN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 30.65 |
| Support Level | $9.82 | $26.80 |
| Resistance Level | $10.40 | $27.95 |
| Average True Range (ATR) | 0.52 | 1.07 |
| MACD | -0.06 | 0.16 |
| Stochastic Oscillator | 25.00 | 1.37 |
Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Materials. It derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.